1 row is stored for this page
| Field | Field type | Value |
|---|
| generic | String | Tobramycin |
| brand | String | Tobrex (ophthalmic), Tobi, Tobi Podhaler, Bethkis (inhaled, cystic fibrosis), generic IV |
| structure | File | |
| classes | List of String, delimiter: , | [[:Category:Aminoglycosides|Aminoglycoside antibiotic]] • [[:Category:Antibacterials|Antibacterial]] |
| mechanism | String | |
| uses | String | '"`UNIQ--vote-000010AF-QINU`"', '"`UNIQ--vote-000010B0-QINU`"', '"`UNIQ--vote-000010B1-QINU`"', '"`UNIQ--vote-000010B2-QINU`"' |
| starting_dose | String | IV: traditional 1-1.7 mg/kg q8h or extended-interval 5-7 mg/kg q24h with target-trough monitoring; inhaled CF 300 mg BID × 28 days on / 28 days off; ophthalmic 1-2 drops in affected eye(s) q4h |
| preparations | String | IV 10 mg/mL, 40 mg/mL; inhaled 300 mg/5 mL solution (Tobi, Bethkis); Podhaler dry powder; 0.3% ophthalmic solution and ointment |
| fda_max | String | IV: monitored by levels (trough <1 mg/L for extended-interval; <2 mg/L for traditional) |
| pill_id | Text | |
| routes | List of String, delimiter: , | IV • IM • inhaled • ophthalmic • intravitreal |
| onset | String | Hours (systemic); minutes (ophthalmic) |
| duration | String | 6-12 hours systemic |
| halflife | String | 2-3 hours (normal renal function); markedly prolonged in renal impairment'"`UNIQ--ref-000010B3-QINU`"' |
| bioavailability | String | IV/IM ~100%; inhaled: minimal systemic; oral: negligible (not used orally for systemic infection)'"`UNIQ--ref-000010B4-QINU`"' |
| pregnancy | String | Aminoglycoside-class ototoxicity in fetal cochlea is documented; use only when alternatives have failed.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> |
| legal | String | [[USLegal:Prescription only|Rx-only]] in US |
